- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02382380
Evaluation of Gadoterate in Patients With Decreased Kidney Function
Evaluation of Gadoterate in Patients With Renal Dysfunction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gadolinium-based intravenous contrast agents are widely used for the enhancement of MRI findings. However, these agents have been implicated in varying degrees of nephrotoxicity and therefore are not usually used in patients with renal dysfunction. Gadoterate is a Gadolinium agent and previous studies have indicated that it is safe in patients with decreased kidney function. The purpose of this study is to evaluate the safety and efficacy of using Gadoterate in this patient population.
Participants who have been scheduled for an MRI will choose to either receive Gadoterate contrast as part of their MRI or not receive Gadoterate as part of their MRI.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Glomerular filtration rates (GFR) less than 30 ml/min but not on dialysis
- Being sent for an MRI examination in the course of routine clinical evaluation of one of the following indications: suspected or known head/neck/brain mass, hepatic mass, renal mass, pancreatic mass, or prostate mass, as well as evaluation of carotid or abdominopelvic vasculature.
Exclusion Criteria:
- Pregnant and lactating females
- Planned initiation of chemotherapy or surgery within 72 hours of the MRI exam
- Hemodynamic instability or acute coronary syndrome
- History of nephrotoxic medication within 2 weeks of the exam
- Less than 18 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gadoterate
Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg).
The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
|
Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg).
The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
Other Names:
|
Other: No Gadoterate
Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast.
MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
|
Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast.
The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glomerular filtration rate (GFR)
Time Frame: 6 months
|
Change in GFR from 0 to 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ari Goldberg, MD, Loyola University
Publications and helpful links
General Publications
- Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008 Aug;21(4):469-90. doi: 10.1007/s10534-008-9135-x. Epub 2008 Mar 15.
- Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5. doi: 10.1007/s00270-011-0287-7. Epub 2011 Oct 19.
- Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006 Dec;16(12):2619-21. doi: 10.1007/s00330-006-0495-8. Epub 2006 Oct 24. No abstract available.
- Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003 Aug;38(2):313-8. doi: 10.1016/s0741-5214(03)00315-x.
- Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009 Feb;4(2):461-9. doi: 10.2215/CJN.06011108. Erratum In: Clin J Am Soc Nephrol. 2009 Apr;4(4):866.
- Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, Choukroun G, Deray G. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. 2010 Feb;73(2):357-9. doi: 10.1016/j.ejrad.2008.11.021. Epub 2009 Jan 6.
- Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006 May-Jun;1(3):128-37. doi: 10.1002/cmmi.100.
- Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol. 2013 May;23(5):1250-9. doi: 10.1007/s00330-012-2705-x. Epub 2012 Dec 5.
- Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol. 2012 May;81(5):885-90. doi: 10.1016/j.ejrad.2011.04.022. Epub 2011 May 8.
- Herborn CU, Honold E, Wolf M, Kemper J, Kinner S, Adam G, Barkhausen J. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007 Jan;42(1):58-62. doi: 10.1097/01.rli.0000248893.01067.e5.
- Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007 Feb;188(2):586-92. doi: 10.2214/ajr.06.1094.
- Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr;65(4):637-42. doi: 10.1002/acr.21877.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 206338
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Dysfunction
-
University Hospital, GenevaPamukkale University; Hospices Civils de Lyon; Hospital Clinic of Barcelona; German... and other collaboratorsUnknownCardiovascular Disease | Non-Dialysis Dependent Severe Renal DysfunctionGermany, France, Spain, Switzerland, Turkey
-
Novartis PharmaceuticalsCompletedHypertension With Renal DysfunctionJapan
-
Solvay PharmaceuticalsTerminatedAcute Decompensated Heart Failure; Renal DysfunctionUnited States, Canada, Chile, Denmark, France, Germany, Italy, Poland, Romania, Russian Federation, Ukraine
-
National Taiwan University HospitalUnknownLong-term Renal DysfunctionTaiwan
-
Seoul National University HospitalCompletedRenal DysfunctionKorea, Republic of
-
Chinese University of Hong KongCompletedChronic Allograft Dysfunction in Renal TransplantationHong Kong
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedHealthy | Renal DysfunctionUnited States
-
National Cancer Institute (NCI)Completed
-
Duke UniversityGlaxoSmithKlineWithdrawnKidney DiseasesUnited States
-
Rocky Mountain Cancer CentersUniversity of Colorado, DenverCompletedMortality | Acute Renal Failure | Renal DysfunctionUnited States
Clinical Trials on Gadoterate
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
GuerbetCompletedMagnetic Resonance ImagingFrance, Austria, Hungary, Poland
-
GuerbetCompletedPeripheral Arterial DiseaseAustria
-
GuerbetRecruitingBrain Tumor, Recurrent | Brain Tumor, PrimaryItaly, Hungary, Poland
-
Massachusetts General HospitalBoehringer IngelheimRecruitingInterstitial Lung DiseaseUnited States
-
Phoenix Children's HospitalGuerbetCompletedIntra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRIBrain DiseasesUnited States
-
GuerbetTerminatedHepatocellular CarcinomaKorea, Republic of
-
GuerbetCompletedType 2 Diabetes Mellitus | Coronary AtherosclerosisKorea, Republic of
-
GuerbetTerminatedRenal DiseaseUnited States
-
University of Massachusetts, WorcesterGuerbetRecruiting